Can Contraceptive Implants Cause Dyspnea or Fatigue?
Dyspnea and fatigue are not recognized side effects of etonogestrel contraceptive implants based on major clinical guidelines and FDA labeling, though one retracted study reported a single case of dyspnea leading to discontinuation.
Evidence from Guidelines and Drug Labels
The major contraceptive guidelines from the CDC 1, American Academy of Pediatrics 2, and other authoritative sources consistently identify bleeding irregularities (amenorrhea, spotting, prolonged bleeding) as the primary side effect and most common reason for implant discontinuation 2, 1. Neither dyspnea nor fatigue appear in the standard counseling recommendations for common side effects.
The FDA drug label for etonogestrel 3 does not list dyspnea or fatigue as adverse effects in its clinical trial data or warnings sections. The label focuses on cardiovascular risks (VTE), bleeding patterns, and insertion/removal complications.
Limited Research Evidence
Only one study mentions dyspnea in relation to etonogestrel implants:
A 1999 pilot study in Indonesia (n=200) reported one case of dyspnea that led to discontinuation over 4 years 4. However, this study has been retracted, significantly undermining its credibility.
A 2022 case series described dyspnea in patients with implant migration into the pulmonary artery 5—an extremely rare complication unrelated to the hormonal effects of the device itself.
A 2026 quality of life study found no impact on sexual function but noted decreased psychological, social, and environmental quality of life scores 6. This study did not specifically assess dyspnea or fatigue as outcomes.
Clinical Interpretation
If a patient using an etonogestrel implant presents with dyspnea or fatigue, these symptoms should not be attributed to the contraceptive implant without thorough evaluation for other causes. Consider:
Anemia from irregular bleeding: The implant commonly causes unpredictable bleeding patterns 1. Chronic blood loss could lead to iron-deficiency anemia, which manifests as fatigue and exertional dyspnea. Check hemoglobin/hematocrit and iron studies.
Cardiovascular events: While the implant itself has minimal cardiovascular risk compared to combined hormonal contraceptives 3, evaluate for VTE, especially if the patient has additional risk factors.
Device migration: Extremely rare, but pulmonary artery migration can cause cardiopulmonary symptoms 5. Consider if there's evidence the implant is not palpable in the arm.
Unrelated medical conditions: Thyroid disorders, cardiac disease, pulmonary conditions, depression, and many other causes of dyspnea/fatigue should be investigated.
Common Pitfalls
- Do not dismiss these symptoms as implant-related without proper workup
- Do not remove the implant as first-line management without identifying an actual cause
- Do evaluate for anemia secondary to implant-related bleeding, which is a plausible indirect mechanism
The contraceptive implant should remain in place while investigating other causes of dyspnea and fatigue, unless a specific contraindication to continued use is identified.